

Daily evidence digest

28 January 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Reinfection risk after SARS-CoV-2, potential indirect impacts of COVID-19 on Australian children, immunoglobulin predictor of post-acute COVID-19

Peer reviewed journals featured:

- A rapid review on risk for reinfection after SARS-CoV-2 [here](#)
- A narrative review on potential indirect impacts of COVID-19 on children in Australia [here](#)
- Randomised trials on:
 - AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults [here](#)
 - The SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults [here](#)
- Observational studies on:
 - Carditis after Comirnaty (Pfizer) and CoronaVac (Sinovac) vaccination [here](#)
 - Myocarditis cases after mRNA-based vaccination in the US [here](#)
 - COVID-19 reinfections among naturally infected and vaccinated individuals [here](#)
 - Immunoglobulin predictor of the risk of post-acute COVID-19 syndrome [here](#)
 - SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1) [here](#)
 - The emergence of COVID-19 associated mucormycosis in 18 countries [here](#)
- An editorial on “the STEMI phenomenon” in COVID-19 [here](#)
- Commentary on:
 - New Zealand’s COVID-19 strategy and the impact on Māori people [here](#)
 - Vaccination of people from 12 years of age for COVID-19 against parents’ wishes [here](#)

Letters and correspondence discussed:

- Omicron neutralising antibodies after third COVID-19 vaccine dose in cancer patients [here](#)

Pre-peer review articles featured:

- Vaccine effectiveness against Omicron in patients receiving haemodialysis [here](#)
- Neutralising immunity in vaccine breakthrough infections from the Omicron and Delta variants [here](#)
- Neutralising breadth against SARS-CoV-2 variants after three doses of mRNA vaccine [here](#)
- Spikevax (Moderna) vaccine-elicited neutralisation of Omicron in adolescents and children [here](#)
- Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time [here](#)
- The Omicron variant and its infection advantage over Delta in vaccinated persons [here](#)
- The Australian First Few X household transmission project for COVID-19 [here](#)
- Projection of healthcare demand in Germany and Switzerland in the Omicron wave [here](#)
- Post-COVID-19 memory impairment [here](#)

Guidance and reports

- The World Health Organization published:
 - Updates of its COVID-19 vaccine tracker [here](#), COVID-19 epidemiological report [here](#), and operational report [here](#)
 - Background document re guidance for the Novavax vaccine [here](#)
- The American College of Physicians released Living practice points on the antibody response and its role in conferring natural immunity after SARS-CoV-2 infection [here](#)

News and blogs

- One in 23 people in England had infection in early January [here](#)
- CoronaVac immunity is strongest after boosting with a different vaccine [here](#)
- Europe could be headed for pandemic “endgame” [here](#)
- NEJM audio interview on COVID-19 learnings from the Ebola crisis [here](#)
- Post-acute COVID-19 syndrome symptoms less likely in vaccinated people [here](#)
- COVID-19 and the common cold [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).